Heart Failure
Conditions
Keywords
Heart Failure,, PET Imaging,, Implantable Cardioverter-Defibrillator,, Sudden Cardiac Death
Brief summary
The purpose of this clinical study is to determine the optimal imaging parameters and assess the safety of LMI1195 -101 in Heart Failure subjects at Low and High Risk of cardiac events.
Detailed description
* To determine the optimal imaging protocol for a single dose of LMI1195 during positron emission tomography (PET) for the intended study population. * To assess the safety and tolerability of LMI1195 in patients at low risk of ventricular arrhythmia (low risk patients) and heart failure patients with a history of firing of an implantable cardioverter defibrillator (ICD) within 6 months prior to enrollment, a documented ejection fraction (EF) ≤ 35%, and a prior diagnosis of NYHA Class II-III heart failure (heart failure patients) who are undergoing PET imaging.
Interventions
DRUGLMI 1195
Single bolus intravenous injection of LMI 1195
Sponsors
Lantheus Medical Imaging
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or non-pregnant female ≥ 18 years of age * a body weight that is \<450 pounds * Be able to lie flat for at least 2-hour intervals * Have a normal left ventricular ejection fraction (i.e., ≥ 55% for cohort one or ≤35% for cohort two) by multiple gate acquisition scan (MUGA), echocardiogram or single photon emission computed tomography (SPECT) within 90 days prior, but no less than 3 days prior to enrollment. * Have been scheduled to undergo or have undergone a SPECT or an approved PET perfusion imaging study performed within 90 days prior to, but no less than 3 days prior to enrollment. to and within the study timeline must be reviewed and deemed acceptable by the judgment of the investigator) (Additional More Specific Criteria can be accessed by contacting an LMI representative)
Exclusion criteria
* Have a history of diabetes, coronary artery disease, myocardial infarction heart arrhythmia (except sinus arrhythmia), heart failure, cardiomyopathy (e.g. restrictive, infiltrative or hypertrophic cardiomyopathy), constrictive pericarditis, myocarditis, complex congenital disease, surgically correctable valvular disease, and/or inoperable, obstructive valvular disease, pacemaker, syncope, transient ischemic attack (TIA) or cerebrovascular accident (CVA), Parkinson's disease, degenerative cerebral disease, or organ transplantation.significant comorbid conditions * Have undergone major surgery within 4 weeks prior to enrollment or planned within 3 weeks after completion of the study. * Unexplained syncope within 5 years. * A life expectancy of \< 1 year, from any cause. * Are currently participating in another clinical trial of an investigational product. * Have clinically significant laboratory abnormalities (e.g., liver enzymes, creatinine, etc.). * Have a history of smoking within 1 month of enrollment. * History of drug or alcohol abuse * Have a history of major psychiatric disorder, active alcohol/drug abuse, and/or history of non-compliance. * Receipt of any radiopharmaceutical within a period equal to 10 half-lives of the isotope (e.g., for 99mTc, a period of 60 hours; for 111In, a period of 28 days) prior to enrollment or receipt of any radiopharmaceutical containing iodine within a period of 3 months prior to enrollment. * Have received any of the following medications within 30 days prior to enrollment, because of confounding effects to the autonomic nervous system: albuterol (Alupent, Ventolin within 24 hours), Dobutamine (Dobutrex), Dopamine (Intropin), Epinephrine (Adrenalin), Isoproterenol, Phenylephrine (Neo-Synephrine), Metaraminol (Aramine), Norepinephrine (Levophed), furazolidone (Furoxone), tricyclic antidepressants (Adapin, Asendin, Aventyl, Elavil, Endep, Norpramin, Pamelor, Sinequan, Surmontil, Tofranil, Vivactil), guanethidine (Ismelin), methyldopa (Aldomet). Over the counter herbs that have been reported to interact with adrenergic amines are excluded: ephedra (ma huang), St. John's wort; alfalfa; hibiscus; ginseng; angelica (dong quai); and yohimbe. * Are not suitable subjects for completion of any screening or trial procedures including PET, scans & laboratory testing, * Receipt of any radiopharmaceutical within a period of time that the agent has not decayed below background levels * Have metal that cannot be removed from the body located in the thorax, Receiving Class I or III antiarrhythmic drug therapy, except for amiodarone. (Additional More Specific Criteria can be accessed by contacting an LMI representative)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dose acquisition time product, target and non-target F18 count density | Approximately one year |
Secondary
| Measure | Time frame |
|---|---|
| Assess Image Quality Data Variability across age & sex stratification Determine Retention Index Values Determine Heart to Mediastinal Ratio Evaluate additional image derived markers that may have predictive value | Approximately one year |
Countries
United States
Outcome results
None listed